German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn - Update 2008

European Journal of Medical Research

Volumn 14, Issue 11, 2009, Pages 461-479

  Buchholz, Bernd ^a   Beichert, Matthias ^b   Marcus, Ulrich ^c   Grubert, Thomas ^d   Gingelmaier, Andrea ^d   Haberl, Annette ^e   Schmied, Brigitte ^f  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Gynecology and Obstetrics Joint Practice   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f Otto Wagner Spital   (Austria)

Author keywords

Anti retroviral drugs; HIV status; HIV testing; HIV therapy; Pregnancy; Recommendations

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

AMNIOCENTESIS; AUSTRIA; BREAST FEEDING; CESAREAN SECTION; CONGENITAL MALFORMATION; DELIVERY ROOM; FIRST TRIMESTER PREGNANCY; GENE THERAPY; GERMANY; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABOR ONSET; MEDICAL SPECIALIST; MIXED INFECTION; NONHUMAN; POSTNATAL CARE; PRACTICE GUIDELINE; PREGNANCY; PRENATAL CARE; REVIEW; RISK ASSESSMENT; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 72249083106     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-14-11-461     Document Type: Review

References (141)

1. Bundeszentrale für gesundheitliche Aufklärung, Köln: Aids von A bis Z; Neuauflage 2002
2. Deutsche AIDS-Hilfe e.V.: Der heutige Wissensstand 28. überarbeitete Auflage, 2002
3. Mayaux MJ, Dussaix E, Isopet J et al.: Maternal Virus Load during Pregnancy and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1: The French Perinatal Cohort Studies. J Infect Dis 1997; 175: 172-175 (Pubitemid 27020842)
4. Sperling RS, Shapiro DE, Coombs RW et al.: Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. N Engl J Med 1996; 335: 1621-1629
5. Cooper ER, Charurat M, Mofenson L et al.: Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. JAIDS 2002; 29:484-494 (Pubitemid 34456340)
6. Poirier MC, Divi RL, Al-Harthi L et al.: Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. JAIDS 2003; 32: 175-183 (Pubitemid 36793152)
7. Barret B, Tardieu M, Rustin P et al.: Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17: 1769-1785 (Pubitemid 37000095)
8. Blanche S, Tardieu M, Rustin P et al.: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-1089 (Pubitemid 29452821)
9. Poirier MC, Patterson TA, Slikker Jr. W, Olivero OA: Incorporation of 3′-Azido-3′-Deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. JAIDS 1999; 22: 477-483
10. Meng Q, Walker DM, Olivero OA et al.: Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci USA 2000; 97: 12667-12671 (Pubitemid 30840473)
11. Scalfaro P, Chesaux JJ, Buchwalder PA et al.: Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med 1998; 24: 247-250 (Pubitemid 28190817)
12. European Collaborative Study: Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. JAIDS 2003; 32: 380-387
13. Wahn V: Routinemäßige Gabe von Zidovudin an HIV-infizierte Schwangere. Dt Ärztebl 1995; 92:A-3397-3398
14. Frenkel LM, Cowles MK, Shapiro DE et al.: Analysis of the Maternal Components of the AIDS Clinical Trial Group 076 Zidovudine Regimen in the Prevention of Mother-to-Infant Transmission of Human Immunodeficiency Virus Type 1. J Infect Dis 1997; 175: 971-974
15. Landesmann SH, Kalish LA, Burns DN et al.: Obstetrical Factors and The Transmission of Human Immunodeficiency Virus Type 1 from Mother to Child. N Engl J Med 1996; 334: 1617-1623 (Pubitemid 26192520)
16. Mandelbrot L, Le Chenadec J, Berrebi A et al.: Perinatal HIV-1 Transmission. Interaction between Zidovudine Prophylaxis and Mode of Delivery in the French Perinatal Cohort. JAMA 1998; 280: 55-60
17. Pitt J, Brambilla D, Reichelderfer P et al.: Maternal Immunologic and Virologic Risk Factors for Infant Human Immunodeficiency Virus Type 1 Infection: Findings from the Women and Infants Transmission Study. J Infect Dis 1997; 175: 567-575 (Pubitemid 27086159)
18. Rokos K, Wang H, Seeger J et al.: Transport of Viruses Through Fetal Membranes: An In Vitro Model of Perinatal Transmission. J Med Virology 1998; 54: 313-319 (Pubitemid 28185425)
19. The European Collaborative Study: Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996; 10: 1675-1681
20. The European Collaborative Study: Immunological markers in HIV-infected pregnant women. AIDS 1997; 11: 1859-1865
21. Tuomala RE, O'Driscoll PT, Bremer JW et al.: Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. JID 2003; 187: 375-384
22. Bums DN, Landesman S, Wright, DJ et al.: Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997;175:1206-1210 (Pubitemid 27176512)
23. Gaillard P, Verhofstede C, Mwanyumba F et al.: Exposure to HIV-1 during delivery and mother-to-child transmission. AIDS 2000; 14: 2341-2348 (Pubitemid 30832104)
24. Wright TC Jr, Subbarao S, Ellerbrock TV et al.: Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol. 2001; 184: 279-285 (Pubitemid 32206972)
25. Mwanyumba F, Gaillard P, Inion I et al.: Placental inflammation and perinatal transmission of HIV-1. JAIDS 2002; 29: 262-269 (Pubitemid 34208534)
26. Kind Ch, Rudin Ch, Siegrist C et al.: Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. AIDS 1998; 12: 205-210 (Pubitemid 28035162)
27. Schäfer APA: Die HIV-Infektion in Geburtshilfe und Gynäkologie. Gynäkologe 1996; 29:129-137
28. Schäfer A, Friese K, Lauper U et al.: Influence of cesarean section before parturition and antiretroviral prophylaxis on the materno-fetal transmission of HIV. 12th World AIDS Conference Geneva, June 28-July 3 1998, Poster LB 12466
29. Salzberger B, Marcus U, Vielhaber B et al.: German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res. 2004; 9(11): 491-504 URL: http://www.daignet.de unter Leitlinien
30. Coll O, Fiore S, Floridia M et al.: Pregnancy and HIV infection: A european consensus on management. AIDS 2002; 16 (Suppl 2): S1-18
31. CDC Public Health Service Task Force: Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. MMWR 1998; 47/ RR2
32. CDC: Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. MMWR 1998; 47/ RR-5
33. Justman JE, Benning L, Danoff A et al.: Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. JAIDS 2003; 32: 298-302
34. Lorenzi P, Spicher VM, Laubereau B et al. (Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study): Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998; 12 (18): F 241-247 (Pubitemid 28558591)
35. Wimalasundera RC, Larbalestier N, Smith JH et al.: Preeclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002, 360: 1152-1154
36. Tuomala RE, Shapiro DE, Mofenson LM et al.: Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-1870
37. Conley LJ, Ellerbrock TV, Bush TJ et al.: HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359: 108-113
38. Vandamme AM, Sonnerborg A, Ait-Khaled M et al.: Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9(6): 829-848
39. Welles SL, Pitt J, Colgrove R and The Women and Infants Transmission Study Group: HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS 2000; 14:263-271
40. Duwe S, Brunn M, Altmann D et al.: Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. JAIDS 2001; 26: 266-273 (Pubitemid 32246557)
41. Eastman PS, Shapiro DE, Coombs RW et al.: Maternal Viral Genotypic Zidovudine Resistance and Infrequent Zidovudine Therapy to Prevent Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Pediatric Clinical Trial Protocol 076. J Infect Dis 1998; 177: 557-564
42. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C et al.: Lamivudine-Zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-2093 (Pubitemid 32367825)
43. Jackson JB, Becker-Pergola G, Guay LA et al.: Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14: F111-F115 (Pubitemid 30687669)
44. Eshleman SH, Hoover DR, Chen S et al.: Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192(1): 30-36 (Pubitemid 40863854)
45. Sustiva Capsules Product Monograph 1998
46. BMS Warning Letter, 5. January 2001
47. Rich KC, Siegel JN, Jennings C et al.: CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. J Infect Dis 1995; 172: 1221-1227 (Pubitemid 3002582)
48. Kosel BW, Beckerman KP, Hayashi S et al.: Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17: 1195-1199 (Pubitemid 36667762)
49. Mirochnick M, Fenton T, Gagnier P et al.: Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178: 368-374
50. Wang Y, Livingston E, Paul S, et al.: Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis 1999; 180: 1536-1541 (Pubitemid 29506455)
51. Qian M, Bui T, Ho RJY et al.: Metabolism of 3′-Azido-3′- Deoxythymidine (AZT) in Human Placental Trophopblasts and Hofbauer Cells. Biochemical Pharmacology 1994; 48: 383-389 (Pubitemid 24243982)
52. Agbaria R, Manor E, Barak J et al.: Phosphorylation of 3′-Azidothymidine in maternal and fetal peripheral blood mononuclear cells during gestation and and at term. JAIDS 2003; 32: 477-481
53. Taylor GP, Lyall EGH, Back D et al.: Pharmacological implications of lengthened in-utero exposure to nevirapine. Lancet 2000; 355: 2134-2135 (Pubitemid 30364665)
54. Marzolini C, Rudin C, Decosterd LA et al.: Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16: 889-893
55. Mirochnick M, Dorenbaum A, Holland D et al.: Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002; 21(9): 835-838
56. Mirochnick M, Dorenbaum A, Blanchard S et al.: Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. JAIDS 2003; 33(2): 153-156
57. Antiretroviral Pregnancy Registry Steering Committee: Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2007; Issued Dec 2007 available from url:www.apregistry.com
58. Larsen WJ: Human Embryology. New York: Churchill Livingstone, 1993
59. Wilson JD, Frazer FC (Hrsg.): Handbook of Teratology, Vol.I. New York: Plenum Press, 1977
60. Spielmann H, Steinhoff R, Schaefer C et al.: Arzneiverordnung in Schwangerschaft und Stillzeit. 5. Aufl., Stuttgart, Gustav Fischer,1998
61. Connor EM, Sperling RS, Gelber R et al.: Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment. N Engl J Med 1994; 331:1173-1180
62. Chuachoowong R, Shaffer N, Siriwasin W et al.: Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J Inf Dis 2000; 181: 99-106 (Pubitemid 30049038)
63. Lallemant M, Jourdain G, Le Coeur S et al.: A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Eng J Med 2000; 343: 982-991 (Pubitemid 30740497)
64. Wade NA, Birkhead GS, Warren BL et al.: Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1409-1414
65. Mbori-Ngacha D, Richardson BA, Overbaugh J et al.: Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments. J Virol 2003; 77: 7702-7705 (Pubitemid 36734543)
66. Ekpini RA, Nkengasong JN, Sibailly T et al.: Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 2002; 16: 625-630 (Pubitemid 34218859)
67. Sabbatini F, Prati F, Borghi V. et al. : Congenital pyelectasis in children born from mothers on Tenofovir containing therapy during pregnancy : report of two cases. Infection 2007; 35: 474-476 (Pubitemid 50005160)
68. Bardeguez AD, Shapiro DE, Mofenson LM et al.: Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. JAIDS 2003; 32: 170-181
69. Clarke JR, Braganza R, Mirza A et al.: Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999; 59:364-368 (Pubitemid 29468080)
70. O'Sullivan M, Boyer P, Scott G et al.: The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082). Am J Obstet Gynecol 1993; 168: 1510-1516
71. Garcia PM, Kalish LA, Pitt J et al.: Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Eng J Med 1999; 341: 394-402 (Pubitemid 29362512)
72. Mofenson LM, Lambert JS, Stiehm ER et al.: Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Eng J Med 1999; 341: 385-393 (Pubitemid 29362511)
73. The European Collaborative Study: Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13: 1377-1385
74. Shaffer N, Roongpisuthipong A, Siriwasin W et al.: Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. J Inf Dis 1999; 179: 590-599 (Pubitemid 30016142)
75. Semprini AE: An international randomised trial of mode of delivery in HIV infected women. 12th World AIDS Conference Geneva, June 28-July 3 1998, Poster LB 23599
76. The International Perinatal HIV Group: The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - a meta-analysis of 15 prospective cohort studies. N Eng J Med 1999; 340: 977-987
77. CDC: Recommendations of the U-S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus. MMWR 1994; 43/RR-11
78. Grosch-Wörner I, Schäfer A, Obladen M et al.: An effective and safe protocol involving zidovudine and caesarean section to reduce vertical transmission of HIV-1 infection. AIDS 2000; 14: 2903-2911 (Pubitemid 32042754)
79. Burns DN, Landesman S, Muenz LR et al.: Cigarette smoking, premature rupture of membranes and vertical transmission of HIVl among women with low CD4+ levels. JAIDS 1994; 7: 718-726 (Pubitemid 24195830)
80. Wensing MJ, Boucher CAB, van Kasteren M et al.: Prevention of mother-tochild transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. AIDS 2006; 20: 1465-1467
81. Stringer JSA, Sinkala M, Chapman V et al.: Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 2003; 17: 1659-1665 (Pubitemid 36951686)
82. Taha TE, Kumwenda NI, Hoover DR et al.: Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004; 292(2): 202-209
83. Lallemant M, Jourdain G, Le Coeur S et al. Perinatal HIV Prevention Trial (Thailand) Investigators: Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004; 351(3): 217-228
84. Dabis F, Bequet L, Ekouevi DK et al.: ANRS 1201/1202 DITRAME PLUS Study Group: Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19(3): 309-318.
85. Garcia-Tejedor A, Perales A, Maiques V: Duration of ruptured membranes and extended labor are risk factors for HIV transmission. Int J Gynaecol Obstet. 2003; 82(1): 17-23. (Pubitemid 36808588)
86. Deutsch-Österreichische Empfehlungen zur postexpositionellen Prophylaxe nach HIV-Exposition (September 2004) URL: http://www.rki.de
87. Guay LA, Musoke P, Fleming T et al: Intrapartum and neonatal single dose nevirapine compares with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda. HIVNET 012 randomized trial. Lancet 1999; 354: 795-802
88. Moodley D, Moodley J, Coovadia H et al.: A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725-735 (Pubitemid 36286932)
89. Flys T, Nissley DV, Claasen CW et al.: Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192(1): 24-29 (Pubitemid 40863853)
90. Marcus U: AIDS und HIV-Infektionen bei Frauen und Kindern in Deutschland. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 1999; 42: 553-557
91. Shapiro D, Tuomala R, Samelson R et al. Abstract 12953, 9th Conference on Retroviruses and Opportunistic Infections, Seattle 2002
92. Ioannidis JPA, Abrams EJ, Ammann A et al.: CM: Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Inf Dis 2001; 183: 539-545 (Pubitemid 32147509)
93. Mandelbrot L, Burgard M, Teglas J-P et al.: Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS 1999; 13: 2143-2149 (Pubitemid 29509592)
94. Debiaggi M, Zara F, Spinillo A et al.: Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy. Eur J Microbiol Infect Dis 2001; 20: 91-96 (Pubitemid 32247103)
95. Ellerbrock TV, Lennox JL, Clancy KA et al.: Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis 2001, 184: 28-36 (Pubitemid 32568497)
96. Si-Mohamed A, Kazatchkine MD, Goujon C et al.: Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis 2000, 182: 112-122 (Pubitemid 30497795)
97. Avidan MS, Groves P, Blott M et al.: Low complication rate associated with cesarean section under spinal anesthesia for HIV-1-infected women on antiretroviral therapy. Anesthesiology 2002; 97(2): 320-324 (Pubitemid 34847742)
98. Read J, Tuomala R, Kpamegan E et al.: Mode of delivery and postpartum morbidity among HIV-infected women: the women and infants transmission study. JAIDS 2001; 26: 236-245 (Pubitemid 32246553)
99. Rodriguez EJ, Spann C, Jamieson D et al.: Postoperative morbidity associated with cesarean delivery among human immunodeficiency virus-seropositive women. Am J Obstet Gynecol 2001, 184:1108-1111
100. Watts DH, Lambert JS, Stiehm ER et al.: Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of < or = 500/microL. Am J Obstet Gynecol 2000; 183:100-107
101. European Collaborative Study and the Swiss Mother + Child HIV Cohort Study: Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-2920
102. Nduati R, John G, Mbori-Ngacha D et al.: Effect of breastfeeding and formula feeding on Transmission of HIV-1. JAMA 2000; 283: 1167-1174
103. Van de Perre P.: Transmission of human immunodeficiency virus type 1 through breast-feeding: how can it be prevented? J Infect Dis. 1999; 179 Suppl 3: S405-407
104. Nduati RW, John GC, Richardson BA et al.: Human immunodeficiency virus type 1 infected cells in breast milk. Infect Dis 1995; 172: 1461-1468
105. Thiry L, Spencer-Goldberger S, Jonckheer T et al.: Isolation of AIDS virus from cell-free breastmilk of three healthy virus carriers. Lancet 1985 ii: 891-892 (Pubitemid 16242690)
106. Haas J, Geiss M, Böhler T et al.: False-negative polymerase chain reaction-based diagnosis of human immunodeficiency virus type 1 in children infected with HIV strains of African origin. J Infect Dis 1996; 174: 224-225 (Pubitemid 26255589)
107. Rossi P, et al.: Early diagnosis of HIV infection in infants - Report of a consensus workshop, Siena, Italy, January 17-18, 1992. JAIDS 1992; 5: 1168-1178
108. CENTERS OF DISEASE CONTROL: Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998; 47: 1-43; URL http://www.hivatis. org
109. Capparelli EV, Mirochnick M, Dankner WM et al.: Pediatric AIDS Clinical Trials Group 331 Investigators: Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142(1): 47-52
110. Maiques V, Garcia-Tejedor A, Perales A et al: HIV detection in amniotic fluid samples. Amniocentesis can be performed in HIV pregnant women? Eur J Obstet Gynecol Reprod Biol 2003; 108(2): 137-141
111. Davies G, Wilson RD, Desilets V et al.: Society of Obstetricians and Gynaecologists of Canada: Amniocentesis and women with hepatitis B, hepatitis C or human immunodeficiency virus. J Obstet Gynaecol Can 2003; 25(2): 145-148, 149-152
112. Poirier MC, Olivero OA, Walker DM et al.: Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004; 199(2): 151-161
113. Mirochnick M, Capparelli E et al.: Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43(15): 1071-1087
114. Lyons FE, Coughlan S, Byrne CM et al.: Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005; 19(1): 63-67 (Pubitemid 40111019)
115. Nolan M, Fowler MG, Mofenson LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr. 2002; 30(2): 216-229 (Pubitemid 34664419)
116. Thorne C, Patel D, Newell ML: Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18(17): 2337-2339 (Pubitemid 39620231)
117. Fiore S, Newell ML, Thorne C: European HIV in Obstetrics Group: Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery. AIDS 2004; 18(6): 933-938
118. Marcollet A, Goffinet F, Firtion G et al: Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol 2002; 186(4): 784-789 (Pubitemid 34494364)
119. Kovacs A, Wasserman SS, Burns D et al.: DATRI Study Group; WIHS Study Group: Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358(9293): 1593-1601
120. Fiore JR, Suligoi B, Saracino A et al.: Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17(15): 2169-2176 (Pubitemid 37338890)
121. Brennan-Benson p, Pakianathan M, Rice P et al.: Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross plcenta. AIDS 2006; 20: 297-299
122. Chaix ML, Dabis F, Ekouevi D et al.: Addition of 3 Days of ZDV+3TC Postpartum to a Short Course of ZDV+3TC and Single-dose NVP Provides Low Rate of NVP Resistance Mutations and High Efficacy in Preventing Peri-partum HIV-1 Transmission: ANRS DITRAME Plus, Abidjan, Côte d'Ivoire. 12th CROI, Boston 2005, Abstr. 72LB
123. Ripamonti D, Cattaneo D, Maggiolo F et al.: Atazanavir plus low.dose ritonavir in pregnancy : pharmacokinetics and placental transfer. AIDS 2007 ; 21 : 2409-2415 (Pubitemid 350145172)
124. Ioannidis JP, Contopoulos-Ioannidis DG: Maternal viral load and the risk of perinatal transmission of HIV-1. N Engl J Med. 1999; 341(22): 1698-1700
125. Chappuy H, Treluyer JM, Rey E et al.: Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol. 2004; 191(2): 558-562 (Pubitemid 39178714)
126. Feiterna-Sperling C, Piening T, Casteleyn S: Use of lopinavir (LPV/r) during pregnancy Eur J Med Res 10 Supplement II, S. 89 P161.
127. Meyohas MC, Lacombe K, Carbonne B et al.: Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough. AIDS 2004; 18(14): 1966-1968 (Pubitemid 39313217)
128. Morris A, Juethner S, Theroux E: Atazanavir use in pregnancy. Third International AIDS Society Conference on HIV Pathogenesis and Therapy, Rio, poster presentation TuPe5.2p01, 2005.
129. Dunn DT, Brandt CD, Kirvine A et al.: The sensitivity of HIV1-DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995; 9(9): F7-11
130. Chaisilwattana P, Chokephaibulkit K, Chalermchockcharoenkit A et al.: Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. Clin Infect Dis 2002 35(11): 1405-1413
131. European collaborative study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS. 2001 15(6): 761-770
132. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005 40(3): 458-465 (Pubitemid 40216516)
133. Ananworanich J, Siangphoe U, Hill A et al.: Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. JAIDS 2005; 39(5): 523-529 (Pubitemid 41098465)
134. Pellegrin I, Thiebaut R, Blanco P et al.: Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4(+) cells/microl? Impact on immunovirological parameters. J Med Virol 2005; 77(2): 164-172 (Pubitemid 41285782)
135. Tarantal AF, Marthas ML, Shaw JP et al.: Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1999: 20: 323-333.
136. Hughes S, Hughes A, Brothers C et al. on behalf of the CNA106030 Study Team. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat. 2007 May 29; [Epub ahead of print]
137. Warszawski J, Tubiana R, Le Chenadec J et al. Mother to child HIV transmission despite antiretroviral therapy in the ARNS French Perinatal Cohort: AIDS 2008; 22: 289-299
138. Mofenson LM. Efavirenz reclassified as FDA pregnancy category D. AIDS Clin Care. 2005; 17(2): 17.
139. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006 355(22):2283-2296
140. Gingelmaier A, Hollwitz B, Casteleyn S et al. Schwangerschaftsverlauf und kindliches Outcome bei 599 HIV-exponierten Schwangerschaften an deutschen Schwerpunktzentren 1999-2003. Geburtshilfe und Frauenheilkunde 2005, 65: 1058-1063
141. Sadiq ST, Fredericks S, Khoo SH et al. Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. AIDS. 2005; 19(15):1716-1717 (Pubitemid 41502696)